Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.54 |
| ▸ | CRHBP | P24387 | 3/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | DBH | P09172 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3536557 | 0.87 | TTR (0.55) | TTRCRHBPCRHR2SMN1; SMN2DBH | |
| SCHEMBL18639988 | 0.85 | PDGFRB (0.45) | TTRCRHBPCRHR2SMN1; SMN2CA2 | |
| SCHEMBL5366841 | 0.83 | TTR (0.54) | TTRCA2MAPTALDH1A1MEN1 | |
| SCHEMBL30074670 | 0.83 | CA2 (0.68) | TTRCA2MAPTALDH1A1KDM4E | |
| SCHEMBL185845 | 0.83 | CA2 (0.68) | TTRCA2MAPTALDH1A1KDM4E | |
| SCHEMBL11282191 | 0.83 | CA2 (0.68) | CRHBPCRHR2SMN1; SMN2CA2DBH | |
| SCHEMBL334185 | 0.81 | TTR (0.41) | TTRCRHBPCRHR2SMN1; SMN2CA2 | |
| SCHEMBL4976340 | 0.81 | TTR (0.67) | TTRSMN1; SMN2CA2MAPTALDH1A1 | |
| SCHEMBL4482868 | 0.81 | HTT (0.54) | CRHBPCRHR2SMN1; SMN2CA2DBH | |
| SCHEMBL13798155 | 0.80 | MAPT (0.50) | CRHBPCRHR2SMN1; SMN2DBHMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250073236-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | APROS THERAPEUTICS INC (US) | 2025-03-06 | — | — | US | disclosed |
| US-12162902-B2 | Decarboxylase inhibitors for treating Parkinson's disease | SAIL BIOMEDICINES (US) | 2024-12-10 | — | — | US | disclosed |
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | SENDA BIOSCIENCES INC (US) | 2023-06-15 | — | — | US | disclosed |
| CN-110177780-B | Pyrimidine compounds containing acidic groups | 阿普罗斯治疗公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20220048849-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | SENDA BIOSCIENCES, INC. | 2022-02-17 | — | — | US | disclosed |
| EP-3548478-B1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | APROS THERAPEUTICS INC (US) | 2021-11-17 | — | — | EP | disclosed |
| US-11173157-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | Apros Therapeutics, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11173157-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | Apros Therapeutics, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| EP-3891122-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | Senda Biosciences, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| CN-113302176-A | Decarboxylase inhibitors for the treatment of parkinson's disease | 先达生物科技公司 | 2021-08-24 | — | — | CN | disclosed |
| WO-1996022275-A1 | METHOD OF PREPARING RETROVIRAL PROTEASE INHIBITOR INTERMEDIATES | G.D. SEARLE & CO. (US) | 1996-07-25 | — | — | WO | disclosed |
| US-5525614-A | TREATING VASCULAR RESTENOSIS, CNS DISORDERS | WARNER-LAMBERT COMPANY (US) | 1996-06-11 | — | — | US | disclosed |
| US-5489686-A | CARDIOVASCULAR DISORDER, NERVOUS SYSTEM DISORDER, ANTIDIURETIC , PSYCHLOGICAL DISORDER, ANTIDEPRESSANTS | WARNER-LAMBERT COMPANY (US) | 1996-02-06 | — | — | US | disclosed |
| EP-0641326-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES WITH ANGIOTENSIN II RECEPTOR ANTAGONIST PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1995-03-08 | — | — | EP | disclosed |
| US-5350757-A | Treatment of vascular restenosis, nervous system disorders and cognition enhancement | WARNER-LAMBERT COMPANY (US) | 1994-09-27 | — | — | US | disclosed |
| WO-1993023378-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES WITH ANGIOTENSIN II RECEPTOR ANTAGONIST PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1993-11-25 | — | — | WO | disclosed |
| US-5246943-A | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties | WARNER-LAMBERT COMPANY (US) | 1993-09-21 | — | — | US | disclosed |
| US-5081253-A | IMIDAZO(4,5-C)PYRIDINES AS ANTIOSTEOPOROTIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-01-14 | — | — | US | disclosed |
| EP-0434405-A1 | Imidazo[4,5-c]pyridines as antiosteoporotic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1991-06-26 | — | — | EP | disclosed |
| US-4221919-A | Antiinflammatory substituted phenylacetic acids | SPOFA, UNITED PHARMACEUTICAL WORKS (CS) | 1980-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250073236-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | MAVS, TLR7, STING1 | TTR 4788/4885CRHBP 4259/4885CRHR2 4766/4885 |
| US-12162902-B2 | Decarboxylase inhibitors for treating Parkinson's disease | DDC, DDT, DDO | TTR 2018/4885CRHBP 4521/4885CRHR2 4743/4885 |
| US-11173157-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | TLR7, TLR9, MAVS | TTR 4864/4885CRHBP 3741/4885CRHR2 4384/4885 |
| US-20220048849-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | DDC, DDT, DDO | TTR 2018/4885CRHBP 4521/4885CRHR2 4743/4885 |
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | COMT, SNCA, PARK7 | TTR 356/4885CRHBP 1613/4885CRHR2 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.